Abstract:Circulation Research, Ahead of Print. BACKGROUND:Acute ischemic stroke triggers endothelial activation that disrupts vascular integrity and increases hemorrhagic transformation leading to worsened stroke outcomes. rt-PA (recombinant tissue-type plasminogen activator) is an effective treatment; however, its use is limited due to a restricted time window and hemorrhagic transformation risk, which in part may involve activation of MMPs (matrix metalloproteinases) mediated through LOX-1 (lectin-like oxLDL [oxidized low-density lipoprotein] receptor 1). This study's overall aim was to evaluate the therapeutic potential of novel MMP-9 (matrix metalloproteinase 9) and LOX-1 inhibitors in combination with rt-PA to improve stroke outcomes.METHODS:A rat thromboembolic stroke model was utilized to investigate the impact of rt-PA delivered 4 hours poststroke onset as well as selective LOX-1 (BI-0115) and MMP-9 (JNJ0966) inhibitors given before rt-PA administration. Infarct size, perfusion, and hemorrhagic transformation were evaluated by 9.4-T magnetic resonance imaging, vascular and parenchymal MMP-9 activity via zymography, and neurological function was assessed using sensorimotor functioning testing. Human brain microvascular endothelial cells were exposed to hypoxia plus glucose deprivation/reperfusion (hypoxia plus glucose deprivation 3 hours/R 24 hours) and treated with ±rt-PA, ±MMP-9, and LOX-1 inhibitors. Barrier function was assessed via transendothelial electrical resistance, MMP-9 activity was determined with zymography, and LOX-1 and barrier gene expression/levels were measured using qRT-PCR and Western blot.RESULTS:Stroke and subsequent rt-PA treatment increased edema, hemorrhage, MMP-9 activity, LOX-1 expression, and worsened neurological outcomes. LOX-1 inhibition improved neurological function, reduced edema, and improved endothelial barrier integrity. Elevated MMP-9 activity correlated with increased edema, infarct volume, and decreased neurological function. MMP-9 inhibition reduced MMP-9 activity and LOX-1 expression. In human brain microvascular endothelial cells, LOX-1/MMP-9 inhibition differentially attenuated MMP-9 levels, inflammation, and activation following hypoxia plus glucose deprivation/R.CONCLUSIONS:Our findings indicate that MMP-9 and LOX-1 inhibition attenuates negative aspects of ischemic stroke with an rt-PA therapy, thus resulting in improved neurological function. While no synergistic effect was observed with simultaneous LOX-1 and MMP-9 inhibition, a distinct interaction is evident.

Hypoxia Response Element-Regulated MMP-9 Promotes Neurological Recovery Via Glial Scar Degradation and Angiogenesis in Delayed Stroke

Hypoxia-controlled matrix metalloproteinase-9 hyperexpression promotes behavioral recovery after ischemia

Activation of Cerebral Recovery by Matrix Metalloproteinase-9 after Intracerebral Hemorrhage

Ischemic Postconditioning Diminishes Matrix Metalloproteinase 9 Expression and Attenuates Loss of the Extracellular Matrix Proteins in Rats Following Middle Cerebral Artery Occlusion and Reperfusion

Early inhibition of MMP activity in ischemic rat brain promotes expression of tight junction proteins and angiogenesis during recovery.

Matrix Metalloproteinase-9 Expression is Enhanced by Ischemia and Tissue Plasminogen Activator and Induces Hemorrhage, Disability and Mortality in Experimental Stroke

Lentivirus-Mediated Transfer Of Mmp-9 Shrna Provides Neuroprotection Following Focal Ischemic Brain Injury In Rats

Abstract WP298: Matrix Metalloproteinases Are Involved in the Regulation of Angiogenesis after Intracerebral Hemorrhage

Mmp-9, a Potential Target for Cerebral Ischemic Treatment.

Matrix Metalloproteinase-9 Inhibition Attenuates Vascular Endothelial Growth Factor-Induced Intracerebral Hemorrhage

Study of matrix metalloproteinase 9 expression after mice ischemia/reperfusion in hippocampus and treatment effects of Yangyin Tongnao granule(养阴通脑颗粒)

Effect of rt-PA and Edaravone on the Expression of MMP-9 in Rats with Cerebral Ischemic Injury

LOX-1 and MMP-9 Inhibition Attenuates the Detrimental Effects of Delayed rt-PA Therapy and Improves Outcomes After Acute Ischemic Stroke

Abstract WMP38: Inhibition of Rip1 Kinase Improves Brain Functional Recovery after Ischemic Stroke Via Reducing Astrocytic Scar Formation

Targeted Delivery of Extracellular Matrix Protected Against Neurologic Defects after Focal Ischemia Reperfusion in Rats.

ADAMTS13 Deficiency Exacerbates Neuroinflammation by Targeting Matrix Metalloproteinase-9 in Ischemic Brain Injury.

Therapeutic Application of Gene Silencing Mmp-9 in A Middle Cerebral Artery Occlusion-Induced Focal Ischemia Rat Model

Glycine Receptor Beta Subunit (GlyR-β) Promotes Potential Angiogenesis and Neurological Regeneration during Early-Stage Recovery after Cerebral Ischemia Stroke/Reperfusion in Mice

Thrombopoietin Could Protect Cerebral Tissue Against Ischemia-Reperfusion Injury by Suppressing NF-κB and MMP-9 Expression in Rats

A Therapeutic Target Of Cerebral Hemorrhagic Stroke: Matrix Metallo-Proteinase-9

Differences in Acute Expression of Matrix Metalloproteinases-9, 3, and 2 Related to the Duration of Brain Ischemia and Tissue Plasminogen Activator Treatment in Experimental Stroke